<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510535</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL010</org_study_id>
    <nct_id>NCT01510535</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis</brief_title>
  <official_title>An Double-blind, Active-controlled, Parallel-group, Randomized, Multi-center Study to Compare Efficacy and Safety of LBSA0103 Once Versus Hyruan Plus Injection Once Weekly for 3weeks in the Treatment of Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare efficacy and safety of intra-articular LBSA0103 once
      versus intra-articular hyaluronic acid injections (Hyruan Plus Injection) once weekly for 3
      weeks in the treatment of patients with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight-bearing pain</measure>
    <time_frame>12 weeks after the last injection</time_frame>
    <description>using 100mm-VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight-bearing pain</measure>
    <time_frame>1,6 weeks after the last injection</time_frame>
    <description>using 100mm-VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC-likert assessment</measure>
    <time_frame>1,6,12 weeks after the last injection</time_frame>
    <description>Pain, Function, Stiffness, Total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>1,6,12 weeks after the last injection</time_frame>
    <description>using 100mm-VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>1,6,12 weeks after the last injection</time_frame>
    <description>using 100mm-VAS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Placebo and then LBSA0103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyruan Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>First 2 weeks Placebo(2ml) once weekly in experimental group</description>
    <arm_group_label>Placebo and then LBSA0103</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyruan Plus</intervention_name>
    <description>Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group</description>
    <arm_group_label>Hyruan Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBSA0103</intervention_name>
    <description>at third week LBSA0103(60mg) once in experimental group</description>
    <arm_group_label>Placebo and then LBSA0103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 40 years of age

          -  Kellgren &amp; Lawrence grade I-III

          -  If there is more than one knee having a weight bearing pain of at least 40mm evaluated
             by 100mm VAS

          -  Be willing to discontinue all nonsteroidal anti-inflammatory drugs(NSAIDs),
             analgesics, condroichin sulfate/glucosamine or physical therapy for the duration of
             the study

        Exclusion Criteria:

          -  Body mass index &gt; 32

          -  Have rheumarthritis

          -  Patients who have a weight-bearing pain of less than 40mm on both knees when measured
             by 100mm-VAS

          -  Have Sudek's atrophy, Paget's disease, Spinal disc herniation

          -  Kellgren &amp; Lawrence Grade IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoartritis</keyword>
  <keyword>Knee</keyword>
  <keyword>LBSA0103</keyword>
  <keyword>Hyruan Plus Inj.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

